Company / Operating Cash Flow
ResMed Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$1.8B
FY2025
5-year range
$351.1M / $1.8B
FY2021-FY2025
Trend
+25.0%
vs FY2024
Sector context
#22 of 158
Health Care
What the data says
ResMed's operating cash flow of $1.8B is higher than 86% of companies in the Health Care sector (FY2025). Operating Cash Flow has increased for 3 consecutive years, from $351M in FY2022 to $1.8B in FY2025.
Based on SEC 10-K filings.
$1.8B in FY2025 with a 5-year CAGR of +16.9%. Top quartile in the Health Care sector.
Improved from $693M to $1.8B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +70.9%
- 5-Year CAGR
- +16.9%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 158This company $1.8B Sector average $1.0B
▼
+69.6% above sector average
Key checks
Key Insights
- ResMed's operating cash flow has grown for 3 consecutive years.
- 5-year CAGR of +16.9%, indicating consistent growth.
- In FY2025, operating cash flow increased 25.0% year-over-year.
- Ranks #22 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8B | +25.0% |
| FY2024 | $1.4B | +102.1% |
| FY2023 | $693.3M | +97.4% |
| FY2022 | $351.1M | -52.3% |
| FY2021 | $736.7M | -8.2% |
| FY2020 | $802.3M | +74.8% |
| FY2019 | $459.1M | -9.1% |
| FY2018 | $505.0M | +22.0% |
| FY2017 | $414.1M | -24.4% |
| FY2016 | $547.9M | +43.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026